52-week Open Label Safety-Tolerability Study
NCT07369154 · NOVA3 Phase 3Recruiting
- Lead sponsor
- LB Pharmaceuticals Inc. (Industry)
- Enrollment
- 900 (estimated)
- Start date
- 23 Apr 2026
- Primary completion
- Dec 2028 (estimated)
- Study completion
- 1 Apr 2029
- Last update posted
- 9 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- LB-102 Drug
Conditions and primary outcome
- Schizophrenia
Primary outcome
Evaluate long term safety and tolerability of LB-102 by evaluating the number of adverse event, incidence of treatment emergent events. (52 weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07369154.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07369154 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.